For four decades, a mutated protein called KRAS drove pancreatic cancer's lethality while resisting every scientific attempt to stop it — earning the grim designation 'undruggable.' Now, a pill called daraxonrasib has done what generations of researchers could not: in a 501-patient international trial, it doubled median survival for metastatic pancreatic cancer patients, reducing mortality risk by 60 percent in a disease where fewer than one in thirty patients survives five years. The breakthrough, born from a 2013 discovery of a hidden flaw in KRAS's molecular surface, signals not merely a ne
Infobae
· May 13, 2026
· health
· 9 min de leitura
High
Apuração: Verificado
Daraxonrasib duplica supervivencia en cáncer de páncreas metastásico
Pancreatic cancer affects over 500,000 people annually with 470,000 deaths globally; five-year survival at stage four is only 3%, making this therapeutic advance potentially life-extending for thousands of patients.
◉
Health & Medicine
2798 artigos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% correspondência
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% correspondência
WHO endorses GLP-1 weight-loss drugs, issues first clinical guidance a…
El Tiempo · 90% correspondência
Ozempic: Riesgos crecientes por uso estético sin supervisión médica
Medio digital El Zorro Nortino · 90% correspondência
Functional Medicine Shifts Focus to Patient as Active Participant in H…
El País · 90% correspondência
Cobertura Relacionada
El País · Aug 22
La personalidad Ozempic: cómo la delgadez extrema acaba con el placer
Usuarios de fármacos GLP-1 como Ozempic reportan anhedonia, un efecto secundario que les impide disfrutar de actividades…
CNN en Español · Aug 22 Moderna y Merck logran avance decisivo con vacuna personalizada contra el cáncerMerck y Moderna reportan éxito de una vacuna personalizada contra el melanoma que entrena el sistema inmunológico para a…
El Divisadero · Aug 21 Hepatitis virales: herramientas de prevención y cura al alcance en AysénGastroenterólogo del Hospital Regional Coyhaique explica las hepatitis virales, sus formas de transmisión y las herramie…
radiosantamaria.cl · Aug 21 Escuela España suspende clases por brote de enfermedades respiratorias en CoyhaiqueLa Escuela Diferencial España de Coyhaique suspendió clases por 48 horas tras confirmarse un brote de enfermedades respi…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Breakthrough pancreatic cancer drug daraxonrasib doubles survival rates, but this is a medical advancement with minimal direct geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Indirect soft power advantage to the United States through biotech innovation leadership; potential healthcare access disparities between developed and developing nations regarding expensive new treatments.
Lente Econômica
📈
Daraxonrasib doubles pancreatic cancer survival rates, creating major pharmaceutical breakthrough with significant biotech sector implications and potential healthcare cost shifts.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Medical Devices and Diagnostics
Health Insurance
Oncology Research
Patients with metastatic pancreatic cancer gain access to life-extending treatment, though high costs may create affordability challenges and insurance coverage debates. Families face potential financial burden despite improved survival outcomes.
FDA expedited review likely leads to faster approval and market entry. Healthcare systems must develop reimbursement frameworks and pricing policies. Potential pressure for drug price regulation, insurance coverage mandates, and equitable access programs. May influence oncology research funding priorities.